Objective:
To provide an update on the Duravyu clinical trial program (EYP-1901) for retinal exudative diseases, including wet AMD and DME.
Key Findings:
- EYP-1901 demonstrated significant reduction in treatment burden compared to aflibercept.
- Statistically noninferior changes in BCVA were observed at 6 months and 1 year.
- Early therapeutic effects were noted in DME patients as early as 1 month post-injection.
Interpretation:
The EYP-1901 program shows promise for long-term management of wet AMD and DME with fewer injections and a favorable safety profile.
Limitations:
- Phase 3 trials are still ongoing, and results are pending.
- Current data is primarily from earlier phase trials.
Conclusion:
EYP-1901 has shown encouraging durability and safety signals, with potential to reduce treatment burden in retinal diseases.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.